|
|
|
| The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer |
Genta Iwamotoa,Takashi Kawaharaa,b,*( ),Yumiko Yokomizob,Yasuhide Miyoshia,Masahiro Yaob,Hiroji Uemuraa
|
a Department of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
b Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan |
|
|
|
|
Abstract With the spread of prostate-specific antigen (PSA) screening, an increasing number of early-stage prostate cancers have been diagnosed recently, although many patients are still diagnosed in the advanced stage [1]. Although most prostate cancers with metastatic lesions respond to initial androgen ablation therapy, responders ultimately develop progressive disease due to hormone-refractory cancer. Recent studies have shown the efficacy of initial docetaxel or abiraterone acetate with predonine in metastatic hormone-sensitive prostate cancer (mHSPC) [2]. However, not all mHSPC patients experience efficacy with this up-front initial treatment. These previous studies have therefore underscored the importance of assessing the risk of castration-resistant prostate cancer (CRPC) in mHSPC patients.
|
|
Received: 28 May 2019
Available online: 20 July 2021
|
|
Corresponding Authors:
Takashi Kawahara
E-mail: takashi_tk2001@yahoo.co.jp
|
|
|
|
|
The results of neutrophil-to-lymphocyte ratio (NLR) and prostate-specific antigen (PSA) in castration-resistant prostate cancer (CRPC) and NLR group. (A) The lower NLR value group (<1.73) showed a longer time from the initial diagnosis to CRPC than the higher NLR group (≥1.73) (median time: 1067 vs. 426 days, p=0.042); (B) The lower NLR value group (<1.73) showed a longer time from the PSA nadir to CRPC than the higher NLR group (≥1.73) (median time: 426 vs. 215 days, p=0.046); (C) The NLRs at the time of the diagnosis, PSA nadir, and CRPC were 3.36±1.77, 2.24±1.27, and 3.06±1.85, respectively. The NLR at the time of the PSA nadir was significantly lower than the NLR at the diagnosis (p<0.001) but increased again by the point of CRPC (p=0.008).
|
| [1] |
Kawahara T, Yokomizo Y, Ito Y, Ito H, Ishiguro H, Teranishi J, et al. Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer. BMC Canc 2016; 16:111. https://doi.org/10.1186/s12885-016-2134-3.
doi: 10.1186/s12885-016-2134-3
|
| [2] |
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017; 377:352-60.
doi: 10.1056/NEJMoa1704174
|
| [3] |
Gokce MI, Tangal S, Hamidi N, Suer E, Ibis MA, Beduk Y. Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance. Can Urol Assoc J 2016; 10:E383-7. https://doi.org/10.5489/cuaj.3550.
|
| [4] |
Pond GR, Berry WR, Galsky MD, Wood BA, Leopold L, Sonpavde G. Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Clin Genitourin Canc 2012; 10:239-45.
|
| [5] |
Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar- Fadul X, Baird J, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012; 209:495-506.
doi: 10.1084/jem.20111413
|
| [6] |
Nishikawa H, Jager E, Ritter G, Old LJ, Gnjatic S. CD4t CD25t regulatory T cells control the induction of antigen-specific CD4t helper T cell responses in cancer patients. Blood 2005; 106:1008-11.
|
| [7] |
Cantiello F, Russo GI, Vartolomei MD, Farhan ARA, Terracciano D, Musi G, et al. Systemic inflammatory markers and oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. Eur Urol Oncol 2018; 1:403-10.
|
| [8] |
Ferro M, Musi G, Serino A, Cozzi G, Mistretta FA, Costa B, et al. Neutrophil, platelets, and eosinophil to lymphocyte ratios predict gleason score upgrading in low-risk prostate cancer patients. Urol Int 2019; 102:43-50.
doi: 10.1159/000494259
|
| [9] |
Vartolomei MD, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R, et al. Validation of neutrophil-to-lymphocyte ratio in a multi-institutional cohort of patients with T1G3 non-muscleinvasive bladder cancer. Clin Genitourin Canc 2018; 16:445-52.
doi: S1558-7673(18)30183-6
pmid: 30077463
|
| [10] |
Gu X, Gao X, Li X, Qi X, Ma M, Qin S, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients. Sci Rep 2016; 6:22089. https://doi.org/10.5489/cuaj.3550.
doi: 10.1038/srep22089
|
| No related articles found! |
|
|
|
|
